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Objective. The basic mechanisms underlying the pathogenesis of ankylosing spondylitis (AS) remain unresolved. We previously reported an association of the singlenucleotide polymorphism (SNP) rs2549782 in the endoplasmic reticulum aminopeptidase 2 gene (ERAP2) with AS. It is known that patients homozygous for the G allele (GG) of another ERAP2 SNP, rs2248374, lack expression of ERAP2 (ERAP2 null). The present study utilized this information to study the impact of ERAP2 deficiency on HLA-B27 expression in patients with AS, specifically focusing on the functional interaction of ERAP2 and HLA-B27 in peripheral blood mononuclear cells (PBMCs) from patients with AS and assessing the effects in vitro in specific cell lines.
Methods. Expression of intact peptide HLA-B27 (pB27) or the major histocompatibility complex class I free heavy chains (FHCs) was assessed in PBMCs isolated from HLA-B27-positive patients with AS. ERAP2-suppressed, stable B27-expressing C1R cells (C1R-B27) were tested for the expression levels of pB27 and FHCs, as well as for markers of the unfolded protein response (UPR). Distribution of the ERAP2 SNPs rs2549782 and rs2248374 in patients with AS and in patients with Crohn's disease was assessed.
Results. PBMCs from AS patients lacking ERAP2 expressed higher levels of FHCs than did PBMCs from patients positive for ERAP2. This finding was replicated in C1R-B27 cells after suppression of ERAP2. In addition, ERAP2 suppression led to increased levels of the UPR markers BiP, CCAAT/enhancer binding protein homologous protein 10, and X-box binding protein 1 [spliced] as compared to that in short hairpin RNA-treated control cells. There was strong linkage disequilibrium in the ERAP2 locus. All patients with the rs2549782 T allele (which reportedly increases the function of the ERAP-2 protein) were homozygous for the G allele of rs2248374, leading to absence of ERAP2.
Conclusion. ERAP2 deficiency causes increased FHC expression and up-regulation of the UPR pathway.
The pathogenic role of HLA-B27 in ankylosing spondylitis (AS) is not clear. The unfolded protein response (UPR) theory proposes that misfolded HLA-B27 can trigger endoplasmic reticulum (ER) stress. Although definitive demonstration of the UPR in AS has been elusive, in specific cell populations, such as macrophages, the UPR appears to be increased (1) . In HLA-B27-transgenic rats, the misfolding of HLA-B27 in macrophages precedes the UPR, but UPR activation was not seen in splenocytes, further pointing to cell-specific effects (2). We recently reported an increase in HLA-B27 misfolding in the gut of patients with AS and those with Crohn's disease (CD) compared to healthy control subjects, but no up-regulation of the UPR was demonstrated (3).
Endoplasmic reticulum aminopeptidase 2 (ERAP-2) polymorphisms are associated with both CD and AS (4). ERAP-2 is an enzyme involved in trimming of peptides for major histocompatibility complex (MHC) class I loading. Aberrant ERAP-2 function could influence the stability of peptide HLA-B27 (pB27), the formation of MHC class I free heavy chains (FHCs), and the level of ER stress. A structurally and functionally related aminopeptidase, ERAP-1, has also been reported to be associated with AS. We have reported alterations in MHC class I FHC expression in the presence of the ERAP1 singlenucleotide polymorphism (SNP) rs27044 (5) .
Up to 25% of the general population are homozygous for the G allele (GG) of the ERAP2 SNP rs2248374, which leads to alternate splicing and formation of an aberrant messenger RNA (mRNA) that undergoes nonsensemediated decay, resulting in absence of ERAP2 (6). Alternately, in the presence of the T allele of rs2549782, the 392N variant of ERAP2 is encoded, resulting in increased aminopeptidase activity (7). Herein we studied the influence of ERAP2 deficiency, resulting from the presence of the rs2248374 SNP, on HLA-B27 misfolding and the UPR in patients with AS. In addition, we studied the linkage disequilibrium (LD) between SNPs rs2248374 and rs2549782 of ERAP2 in our AS cohort.
PATIENTS AND METHODS
Patients. Study patients comprised sequential HLA-B27-positive patients with AS (diagnosed in accordance with the modified New York criteria [8] ) who were not receiving biologic therapy. We previously reported significantly lower levels of FHCs in patients with AS homozygous for the minor allele of the ERAP1 SNP rs27044 (5). To avoid confounding by ERAP1, we included only patients with the major allele C of the rs27044 SNP (CC/CG). We performed a sensitivity analysis in which we included patients who were homozygous for the G allele (GG). Bath AS Disease Activity Index scores (9), the erythrocyte sedimentation rate, and C-reactive protein levels were collected from all patients.
Genotyping. Peripheral blood cell DNA was genotyped by allelic discrimination assays (Applied Biosystems) for the ERAP1 SNPs rs27044 and rs30187 and the ERAP2 SNPs rs2248374 and rs2549782. Due to strong LD in the ERAP2 locus, we studied the distribution of the ERAP2 SNPs rs2549782 (reported to increase the function of the ERAP-2 protein in vitro) and rs2248374 (reported to lead to absence of ERAP-2 protein expression) in our database of genotyped patients with AS and those with CD. ERAP2 has been linked to both AS and CD. For this study, we had access to a large cohort of patients with CD who were already genotyped for ERAP2. Moreover, by including 2 cohorts of patients, those with AS and those with CD, we were able to increase the sample size and avoid bias from testing just the AS cohort alone. Subsequently, we used the SNP Annotation and Proxy Search (SNAP) tool and the 1000 Genomes Pilot 1 data set (10) .
Flow cytometry. Peripheral blood mononuclear cells (PBMCs) were isolated from patients with AS. In sets of one million PBMCs each, the cells were stained with mouse anti-human HC10 antibodies (for assessment of cell surface FHC) or ME1 antibodies (for identification of pB27), followed by allophycocyanin-conjugated goat anti-mouse IgG as a secondary antibody. Antibodies to CD19 (for identification of B cells) and CD14 (for identification of monocytes) were used to identify individual cell populations. The mean fluorescence intensities (MFIs) of FHC and pB27 expression were each assessed by flow cytometry using a FACSCalibur (BD Biosciences). FHC expression was corrected for HLA-B27 expression by calculating the ratio of HC10 MFI to ME1 MFI. Unstained cells and cells stained with secondary antibody alone were used as a control. Although in C1R-B27 cells, staining with the ME1 antibody is likely to reveal the presence of predominantly pB27, staining with this antibody can recognize other HLA-B alleles, such as B7 and B22, that may be present in patients with AS.
Cell lines and culture conditions. C1R-B27 cells, a human B lymphoblastoid cell line that has low endogenous HLA class I expression and that is stably transfected with HLA-B27, were gifted by Dr. Jos e L opez de Castro (Centro de Biolog ıa Molecular Severo Ochoa, Madrid, Spain). The stable, ERAP2 short hairpin RNA (shRNA)-transfected C1R-B27 cells were maintained in RPMI 1640 medium containing 10% fetal bovine serum, 2 mM glutamine, 50 units/ml penicillin, 50 mg/ml streptomycin, 0.55 mg/ml G418, and 0.1 mg/ml puromycin.
Generation of vector-based ERAP2 RNA-interfering plasmids. Two ERAP2 shRNA oligomers were designed and commercially generated at The Centre for Applied Genomics (Toronto, Ontario, Canada). These oligonucleotides were added with Bam HI and Eco RI restriction sites at the 5 0 and 3 0 ends, respectively (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40033/abstract), and annealed and cloned into a pSiHIV-H1 vector. The resulting plasmids containing shRNA sequences for ERAP2 are hereafter referred to as ERAP2 shRNA1 and ERAP2 shRNA2.
Transduction of HLA-B27-expressing C1R cells. Lentivirus supernatants were generated by transiently transfecting 293T cells with constructed Lenti-PacHIV plasmids. C1R-B27 cells were infected with a lentivirus supernatant containing ERAP2 shRNA plasmids. After infection, the cells were centrifuged and the medium was replaced with 1 ml RPMI 1640. This process was repeated, and after 24 hours, puromycin was added to select stable cells.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Total cellular RNA was isolated with TRIzol reagent and treated with DNase to remove any genomic DNA contamination. Total RNA was quantified in a NanoDrop Bioanalyzer, and complementary DNA was synthesized. Primers used for qRT-PCR analyses are detailed in Supplementary 0 . After amplification, 10 ml of each reaction mixture was detected by 2.5% agarose gel electrophoresis, and the bands were visualized with ethidium bromide, followed by analysis with ImageJ software (National Institutes of Health). GAPDH was used as an internal control.
Western blotting. Protein concentrations were determined with a BCA Protein Assay Kit (Fisher Scientific) from clarified cell lysates. Total protein from cell lysates was separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis mini gels, followed by transfer to nitrocellulose membranes. The antibodies used to probe the membrane were as follows: antibodies to ERAP2 (1:1,000), antibodies to CCAAT/enhancer binding protein homologous protein 10 (CHOP) (1:2,000), and antibodies to b-actin or GAPDH (1:5,000) (all from BD Biosciences). The membrane was incubated with horseradish peroxidase-conjugated antimouse or anti-rabbit antibodies (1:10,000) (Amersham) for 1 hour at room temperature. The membrane was developed using an enhanced chemiluminescence detection system (Fisher Scientific).
Statistical analysis and study approval. All data were analyzed with GraphPad Prism 5 software. The MannWhitney U test was used for comparisons between groups. The Research Ethics Board of the University Health Network (Toronto, Ontario, Canada) approved the studies.
RESULTS
Increased MHC class I FHC expression in AS patients with no ERAP2. We assessed the effect of loss of ERAP2 on HLA-B27 expression in patients with AS. Of 39 patients with AS included in the study (10 of whom were female), 13 were ERAP2 null. The mean 6 SD age of the patients was 41.4 6 13.3 years. There was no significant difference in the baseline characteristics of patients with and those without ERAP2 expression. The distribution of rs30187 and rs27044 ERAP1 SNPs in AS patients with and those without ERAP2 was not significantly different (see Supplementary Tables 3 and 4, available Compared to AS patients with ERAP2, there was significantly higher FHC expression on PBMCs from ERAP2-null patients with AS (P 5 0.009) ( Figure 1A ), specifically the expression of FHCs on monocytes (P 5 0.045) ( Figure 1B) . When corrected for pB27 expression, there was a significantly higher FHC:pB27 ratio in all PBMCs (P 5 0.002) ( Figure 1C ) as well as monocytes (P 5 0.01) ( Figure 1D ) from ERAP2-null patients with AS. There was a trend toward higher FHC expression on the surface of B cells (significantly different by t-test, but not by Mann-Whitney test) (data not shown). There was no significant difference in pB27 expression between patients with and those without ERAP2 or between those with and those without the ERAP1 SNP rs30187 (data not shown). In 2 patients, only pB27 expression was assessed, because HC10 antibodies did not stain the cells.
An additional sensitivity analysis, which included the 2 previously excluded patients homozygous for the G allele of ERAP1 rs27044, showed that FHC expression was significantly higher with loss of ERAP2 in PBMCs, and that the FHC:pB27 ratio was significantly higher in both PBMCs and monocytes from ERAP2-null patients with AS (see Supplementary Figures 1A-D Figure  2A ). ERAP-2 protein levels decreased by 90% and 70% in the presence of shRNA1 and shRNA2, respectively (Figures 2B-D) .
Similar to the findings in ERAP2-null patients with AS, the expression of FHC was higher in C1R-B27 cells after ERAP2 suppression (Figures 2E and F) . ERAP2 suppression did not significantly change the intensity of ME1 staining of the B27 heterodimer in the presence of Figure 1 . ERAP2 deficiency increases major histocompatibility complex (MHC) class I free heavy chains (FHCs) in peripheral blood mononuclear cells (PBMCs) and monocytes from patients with ankylosing spondylitis (AS). A and B, MHC class I FHC expression was assessed by staining with the HC10 antibody in PBMCs (A) and monocytes (B) from patients with AS. C and D, To correct for HLA-B27 expression, the ratio of mean fluorescence intensity (MFI) of FHC expression to that of intact peptide HLA-B27 (pB27) expression (ratio of HC10 to ME1 antibody staining) on the surface of PBMCs (C) and monocytes (D) was compared between AS patients with ERAP2 expression and those without ERAP2 expression (ERAP2 Null). Symbols represent individual patients; horizontal lines with bars show the mean 6 SD. * 5 P , 0.05; ** 5 P , 0.01. Figure 2 . ERAP2 suppression in C1R-B27 cells increases MHC class I FHC expression. ERAP2 was suppressed in C1R-B27 cells using 2 separate short hairpin RNAs (shRNA1 and shRNA2); a scrambled sequence shRNA (SC) was used as a control. A and B, ERAP2 suppression by the 2 shRNAs was measured by quantitative reverse transcription-polymerase chain reaction (A) and Western blotting (B). C and D, Quantitation of ERAP2 suppression shows a reduction in endoplasmic reticulum aminopeptidase 2 protein by 90% with shRNA1 (C) and 70% with shRNA2 (D) compared to scrambled control shRNA. E and F, HC10 antibodies and flow cytometry were used to detect changes in FHC expression in C1R-B27 cells following suppression of ERAP2 by shRNA1 (C) and shRNA2 (D) compared to scrambled control shRNA. G and H, ME1 staining of the B27 heterodimer did not change with the addition of ERAP2 shRNA1 (G) and slightly decreased with ERAP2 shRNA2 (H) as compared to scrambled control shRNA. In A, C, and D, bars show the mean and SD of triplicate experiments. ** 5 P , 0.01; *** 5 P , 0.001. APC 5 allophycocyanin (see Figure 1 for other definitions). Figure 3 . ERAP2 suppression increases the unfolded protein response (UPR) in C1R-B27 cells. A and B, Following ERAP2 suppression in C1R-B27 cells by ERAP2 short hairpin RNA (shRNA), the UPR was assessed by real-time reverse transcription-polymerase chain reaction (PCR) for the fold change in mRNA expression levels of BiP (A) and CCAAT/enhancer binding protein homologous protein 10 (CHOP) (B), relative to scrambled control shRNA (SC). C and D, CHOP protein expression was assessed by Western blotting (C) and quantified as the relative density of expression (D). E, Semiquantitative PCR was used for the X-box binding protein 1 [spliced] (sXBP1) assay. Increased splicing, relative to unspliced XPB1 (uXBP1), indicates UPR activation. GAPDH was used as a loading control. F and G, The density of the XBP1 spliced bands was normalized to the values for GAPDH (F) and total XBP1 (G). H, ERAP2 expression was suppressed with transfection of C1R-B7 cells with ERAP2 shRNA as compared to that in untransfected cells. I and J, Real-time PCR analysis shows an increase in BiP expression (I) but not CHOP expression (J) after ERAP2 suppression in C1R-B7 cells. Bars show the mean and SD of triplicate experiments. * 5 P , 0.05; *** 5 P , 0.001; **** 5 P , 0.0001.
ERAP2 EFFECTS ON HLA-B27 AND UPR
ERAP2 EFFECTS ON HLA-B27 AND UPRshRNA1 ( Figure 2G ) and it slightly decreased with ERAP2 shRNA2 (Figure 2H) , as compared to the effects of control shRNA. There was no significant reduction in ERAP1 levels in the presence of either of the ERAP2 shRNAs, ruling out the possibility of nonspecific ERAP1 inhibition (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40033/abstract).
Association of ERAP2 suppression with activation of the UPR. Silencing of ERAP2 led to increased expression of BiP (1.42-fold) and CHOP (20-fold), which are key UPR genes ( Figures 3A and B) . At the protein level, CHOP increased 4.1-fold and 2.5-fold, respectively, in the presence of each ERAP2 shRNA as compared to a control, scrambled sequence shRNA (Figures 3C and D) .
XBP1[S] gene expression was higher after ERAP2 suppression with both of the ERAP2 shRNAs compared to the control shRNA ( Figure 3E ). Moreover, compared to the effects of control shRNA, in the presence of the ERAP2 shRNAs, XBP1[S] expression was 4.7-fold higher and 4.3-fold higher for values normalized to the expression of GAPDH and total XBP1, respectively ( Figures 3F and G) .
ERAP2 deficiency differentially affected cells expressing HLA-B7. Unlike the findings in untransfected C1R-B27 cells, there was an increase in the levels of BiP, but no significant increase in the levels of CHOP following 90% suppression of ERAP2 in C1R-B7 cells (Figures 3H-J) .
Strong LD between ERAP2 SNPs. There is known LD between the ERAP2 SNPs (11). The rs2549782 polymorphism, which leads to a K392N change in ERAP2, results in altered aminopeptidase activity (7) . We studied the prevalence of the SNPs rs2549782 and rs2248374 in our research database. ERAP2 is associated with both CD and AS, and in our database, 145 patients with AS and 406 Caucasian patients with inflammatory bowel disease were genotyped for both rs2549782 and rs2248374. There were 141 patients who were homozygous for the rs2549782 T allele of ERAP2 (see Supplementary Table 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40033/abstract). However, all patients who were homozygous for the rs2549782 T allele (rs2248374 GG) were ERAP2 null. Thus, the gainof-function ERAP2 variant 392N is likely not expressed, due to the strong LD with the ERAP2-null allele.
Subsequently, using the SNAP tool and the 1000 Genomes Pilot 1 data set (10), we found strong LD between the 2 AS-associated ERAP2 SNPs rs2549782 and rs2248374 (D 0 5 1, r 2 5 0.90). There are no strong recombination hotspots in the ERAP2-LNPEP area of chromosome 5 that would explain the strong LD in this region (see Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40033/abstract). Thus, in the 1000 Genomes database, there is strong LD in the region of ERAP2, and in our analyses of the AS and CD data sets, all patients homozygous for the gain-of-function ERAP2 variant actually have no ERAP2 expression.
DISCUSSION
Herein we have shown a link between decreased ERAP2 levels, increased surface FHC levels, and UPR activation. We found that HLA-B27-positive patients with AS lacking ERAP2 had higher FHC expression on the surface of PBMCs. In addition, ERAP2 suppression in a B27 cell line led to increased FHC levels and activation of the UPR. Most importantly, although the observed data indicated that changes to surface FHC expression had occurred with decreases in the ERAP2 levels, potentially decreased stability of the pB27 complex could lead to changes in HLA-B27 FHC expression in the ER as well. We studied the major UPR pathways by testing for the expression of BiP, XBP1[S] (the inositol-requiring protein 1 pathway), and CHOP (downstream of both the activating transcription factor 4 and RNA-dependent protein kinase-like endoplasmic reticulum kinase pathways). Our results in C1R-B7 and C1R-B27 cells indicated that UPR activation is more prominent but not exclusive to HLA-B27.
In HLA-B27-transgenic rats, high expression of HLA-B27 correlated with the UPR and preceded the onset of disease. Demonstration of the UPR has been difficult in humans. Up-regulation of the UPR was demonstrated in synovial macrophages from patients with AS and correlated with disease activity (1, 12) . A recent study, which was not corrected for treatment effects, showed no link between the UPR and AS (13) . Our study in lamina propria mononuclear cells derived from the gut of patients with AS and those with CD did not show significant UPR activation (3). However, the observed autophagy activation could mask the UPR by clearing misfolded proteins for cell survival (14) . Studies on the pathogenesis of AS in humans are plagued by the difficulty in obtaining biopsy specimens from affected axial joints. Human UPR studies in these target joints have not been performed.
Strong LD in the region of ERAP2 has been reported before (11) . Two large studies demonstrated that the G allele of rs2248374 is protective in AS (11, 15) . In light of these reports, the possibility remains that it might be feasible to consider the notion that loss of ERAP2 leading to UPR changes has pathogenic significance. Loss of ERAP2 is seen only when patients are homozygous for the G allele of rs2248374 (GG). A large proportion of heterozygous individuals in the control group could tip the analysis toward a higher frequency of the G allele in controls. To date, there is no report comparing the prevalence of ERAP2-null individuals between AS cohorts and controls. It is important to remember that a significant proportion of patients with AS will have ERAP2 deficiency. As we showed in our study, 142 patients with AS or CD (25.7%) were homozygous for the ERAP2-null allele. It is possible that in this subset of patients, ERAP2 deficiency could modify the immuneinflammatory response. In our previous family study, the ERAP2 rs2549782 T allele (conveying increased activity of ERAP-2) in a haplotype with ERAP1 was associated with AS (4). Although we did not test the rs2248374 G allele frequency, due to LD between the ERAP2 rs2549782 T allele and rs2248374 G allele, it is likely that all patients who were homozygous for the rs2549782 risk allele were ERAP2 null.
Extensive ERAP1 genotyping of patients was not done, as this study was designed on the basis of 2 major SNPs (rs27044 and rs30187) with functional consequences that were initially reported to be associated with AS and replicated in multiple cohorts. We have previously shown that patients with AS who have the ERAP1 rs27044 SNP but not the rs30187 SNP have significant alterations in the expression of FHC on monocytes (5). Based on this information, we analyzed only patients with the nonrisk allele of ERAP1 rs27044. However, we cannot rule out the possibility that additional ERAP1 SNPs might have influenced our results. We confirmed that ERAP2 shRNA caused no reduction in ERAP1 levels. Hence, the results seen in the present study are likely to be specific to ERAP2.
Our results differ from those in a recent study by Robinson et al (16) , but our study had important differences, including the use of freshly isolated PBMCs in a larger cohort of patients. We selected patients who were not receiving any biologic drugs. Moreover, in our study, the UPR was tested in vitro to directly establish the impact of ERAP2 suppression with appropriate controls.
In conclusion, the results of this study demonstrate a functional interaction of ERAP2 and HLA-B27. ERAP2 suppression was associated with increased FHC expression and activation of the UPR. Alterations in the fine balance of the ERAP2-HLA-B27-UPR functional interaction could play a role in the pathogenesis of AS.
